Ethyl 2-(4-(benzyloxy)phenyl)thiazole-4-carboxylate, 95.0%, 250mg

tert-Butyl 4-Formylbenzoate>98.0%(GC)5g

TRANS-1,2-DICYANO-1,2-BIS(2,4,5-TRIMETHYL-3-THIENYL)ETHENE, 97%, 1g

5-N-Boc-Hexahydro-pyrrolo[3,4-b]pyrrole, 97.0%, 25g

4-Amino[1,1'-biphenyl]-3-carboxylic acid, 95.0%, 2.5g

(1S,2S)-2-(TERT-BUTOXYCARBONYLAMINO)CYCLOPROPANECARBOXYLIC ACID, 95.0%, 100mg

((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid, 95.0%, 25g

E-Plan phase EPLPHi 10x/0.25 infinity corrected IOS objective. Working distance 5.95 mm

Succinimidyl 4-Azidobutyrate>96.0%(HPLC)500mg

6,7-Dimethoxyisoquinoline, 95.0%, 1g

(2,6-Dioxo-piperidin-4-yl)-acetic acid, 97.0%, 1g

3-((Benzyloxy)methyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one, 98%, 250mg

2-Pentene (cis- and trans- mixture), 95.0%, 1g